Ear Disorders

Register for your FREE account now and join the thousands of healthcare professionals who have depended on us for over 26 years for accurate, concise, and timely drug information.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Ear Disorders Resource Center

Welcome to the MPR Ear Disorders Resource Center, where you will find everything you need to make informed clinical decisions.

Drug Monographs

Click on the subcategory below to find drug monographs for that particular area.

Ear Disorders

News

COSM: Study Finds Insomnia Increases Severity of Tinnitus

For patients with tinnitus, insomnia makes the condition worse.

Sequential Bilateral Cochlear Implantation Ups Life Quality

Significant improvements in disease-related quality-of-life (QoL) measures are seen over time following the sequential placement of bilateral cochlear implants (BiCIs) in children with prelingual deafness.

Supplemental NDA submitted for Prevnar 13 in older adults

Pfizer announced that it has submitted a supplemental NDA (sNDA) to the FDA to expand the use of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) to adults ≥50 years of age for the prevention of pneumococcal disease caused by the 13 serotypes contained in the vaccine.

Zinotic ES available for acute otitis externa

Zinotic ES (chloroxylenol, pramoxine HCl and zinc acetate, from Arbor Pharmaceuticals) is now available for the treatment of acute otitis externa (AOE), also known as "swimmer's ear."

New Drugs

DUTOPROL

5/21/2012

AstraZeneca Pharmaceuticals

Pharmacological Class: Cardioselective β₁-blocker + diuretic.

Active Ingredient(s): Metoprolol succinate extended-release, hydrochlorothiazide; 25/12.5mg, 50/12.5mg, 100/12.5mg; tablets.

Indication: Hypertension.

KORLYM

5/14/2012

Corcept Therapeutics

Pharmacological Class: Cortisol receptor blocker.

Active Ingredient(s): Mifepristone 300mg; tabs.

Indication: To control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and have failed surgery or are not candidates for surgery.

VORAXAZE

5/7/2012

BTG International

Pharmacological Class: Carboxypeptidase enzyme.

Active Ingredient(s): Glucarpidase; 1,000 Units/vial; lyophilized powder for IV injection after reconstitution; preservative-free.

Indication: Treatment of toxic plasma methotrexate (MTX) concentrations (>1 micromole per liter) in patients with delayed MTX clearance due to impaired renal function.